Nisevokitug is a monoclonal antibody commercialized by Novartis, with a leading Phase II program in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). According to Globaldata, it is involved in 8 clinical trials, of which 1 was completed, 5 are ongoing, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Nisevokitug’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Net Present Value Model: Novartis AG's Nisevokitug

Buy the Model

Premium Insights

The gold standard of business intelligence.

Find out more

The revenue for Nisevokitug is expected to reach an annual total of $25 mn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Nisevokitug Overview

Nisevokitug (NIS-793) is under development for the treatment of primary myelofibrosis (PMF), metastatic colorectal cancer (mCRC), metastatic adenocarcinoma of the pancreas, myelodysplastic syndrome, post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF), advanced/metastatic solid tumors including non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), hepatocellular carcinoma (HCC) and clear cell renal cell carcinoma. It is administered through intravenous route. The drug candidate is an antibody targeting transforming growth factor beta 1 (TGFb1). It was under development for the treatment of prostate cancer, metastatic pancreatic ductal adenocarcinoma.

Novartis Overview

Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

The company reported revenues of (US Dollars) US$46,660 million for the fiscal year ended December 2023 (FY2023), an increase of 7.6% over FY2022. In FY2023, the company’s operating margin was 20.5%, compared to an operating margin of 18% in FY2022. In FY2023, the company recorded a net margin of 31.8%, compared to a net margin of 16% in FY2022.

For a complete picture of Nisevokitug’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.